Investment and/or Partnership Opportunities
Arthrodynamic Holdings, LLC is open to potential investment and/or partnership opportunities seeking to gain access to ADH’s patent portfolio for human medical applications. Our flexible business model allows for collaborative research and/or licensing agreements for specific treatment areas, territories, etc. Partners will have access to previous in vitro and in vivo studies, regulatory submissions, manufacturing details, and other information pertinent to due diligence.
Medical Applications
ADH owns a comprehensive patent portfolio covering US and strategic non-US countries, comprised of more than 30 awarded and pending patents related to:
- Treatment of inflammatory osteoarthritis (OA) and/or degenerative joint diseases
- Post arthroscopic surgery synovial joint replacement lavage
- Personalized medicine, cell culturing and cellular therapeutic applications
- Treatment of kidney stones and interstitial cystitis
- Treatment for connective tissue conditions
Status of Development
US Status: preparing to establish IDE in 2018 and initiating first-in-human trials shortly thereafter, and based on ADH’s
- established product formulation
- current FDA-approved cGMP suppliers
- comparative animal pre-clinical safety and effectiveness studies
Non-US Status: While formal submissions to the FDA for this treatment indication are underway, ADH is also pursuing regulatory agencies in other countries as a part of a concurrent commercialization strategy.
